Search

Home > New FDA Approvals > 074 – Roche’s balovaptan for autism; Lutathera for GEP-NETs; SyMRI NEURO for myelin quantitation on MRI; FDA approves human exoskeleton
Podcast: New FDA Approvals
Episode:

074 – Roche’s balovaptan for autism; Lutathera for GEP-NETs; SyMRI NEURO for myelin quantitation on MRI; FDA approves human exoskeleton
Category: Science & Medicine
Duration: 00:06:40
Publish Date: 2018-01-29 07:00:00
Description:

January 29, 2018

0:28 Roche wins FDA's breakthrough therapy label for autism drug https://www.reuters.com/article/us-roche-autism/roche-wins-fdas-breakthrough-therapy-label-for-autism-drug-idUSKBN1FI0HS

1:22 Lutathera (lutetium Lu 177 dotatate) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm

3:14 SyMRI NEURO for myelin quantitation on MRI https://www.prnewswire.com/news-releases/syntheticmr-ab---segmentation-and-quantification-of-brain-tissue-and-industry-first-myelin-volume-measurements-in-symri-now-fda-cleared-300589334.html

3:50 The FDA Approves a Robotic Exoskeleton That Augments Strength https://futurism.com/fda-approved-robotic-exoskeleton-augments-strength/ https://www.cyberdyne.jp/wp_uploads/2017/12/171219_FDA_ENG_1.pdf

Please subscribe rate and review. If you like this podcast please tell your colleagues, Thank you! :) NewFDAApprovals.com

 

 
Total Play: 0